|12/14/17||Illinois Surgical Quality Improvement Collaborative and Pacira Pharmaceuticals, Inc. Announce Collaboration to Minimize Opioid Exposure for Postsurgical Patients|
|Collaboration will develop and distribute evidence-based strategies, education and resources to reduce the overprescribing and optimize the use of opioids across 56 Illinois hospitals
PARSIPPANY, N.J. and EVANSTON, Ill., Dec. 14, 2017 (GLOBE NEWSWIRE) -- The Illinois Surgical Quality Improvement Collaborative (ISQIC), a nationally recognized partnership of 56 Illinois hospitals, and Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), today announced an initiative to jointly develop programs and resou... |
|12/08/17||Pacira Pharmaceuticals to Present at the 2017 BMO Capital Markets Prescriptions for Success Healthcare Conference|
|PARSIPPANY, N.J., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the company is scheduled to present at the 2017 BMO Capital Markets Prescriptions for Success Healthcare Conference at 11:30 AM ET on Thursday, December 14, 2017 in New York City.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archiv... |
|12/07/17||Pacira Announces Promotions of Scott Braunstein, MD, to Chief Operating Officer and Richard Scranton, MD, to Chief Scientific Officer|
|Expanded roles reflect key accomplishments and demonstrated leadership
PARSIPPANY, N.J., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Scott Braunstein, MD, has been named Chief Operating Officer and Richard Scranton, MD, has been named Chief Scientific Officer. In this new role, Dr. Braunstein will oversee the company’s commercial and medical affairs functions while continuing to manage strategy and corporate development at Pacira. As Chie... |
|11/29/17||Cancer Treatment Centers of America® Teams with Pacira Pharmaceuticals, Inc. on Innovative Collaboration to Educate Physicians and Patients about Responsible Opioid Use|
|BOCA RATON, Fla., Nov. 29, 2017 /PRNewswire/ -- Cancer Treatment Centers of America® (CTCA), a national network of five hospitals, and Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company focused on opioid alternatives, today announced a new collaboration dedicated to reducing the risk of opioid dependence among cancer patients. The goal of the Opioid Risk Reduction Initiative—an educational effort focused on responsible use and increased awareness of opioid alternatives—is to improv... |
|11/14/17||Pacira Announces FDA Advisory Committee Meeting to Review sNDA for EXPAREL® as a Nerve Block for Regional Analgesia|
|PARSIPPANY, N.J., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that its supplemental New Drug Application (sNDA) for EXPAREL® (bupivacaine liposome injectable suspension) as a nerve block for regional analgesia will be discussed at a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC). The meeting is tentatively scheduled for February 14-15, 2... |
|11/09/17||Pacira Pharmaceuticals to Present at Two November Healthcare Conferences|
|PARSIPPANY, N.J., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the following two healthcare conferences:
Jefferies 2017 Healthcare Conference in London, on Thursday, November 16, 2017 at 10:00 AM GMT (5:00 AM ET)
Piper Jaffray 29th Annual Healthcare Conference in New York City, on Wednesday, November 29, 2017 at 10:00 AM ET
A live audio webcast of the Pacira presentation... |
|11/08/17||Pacira Pharmaceuticals, Inc. Reports Third Quarter 2017 Financial Results|
|EXPAREL(R) net product sales of $66.8 million up 3% over prior year third quarter; Full-year EXPAREL net product sales guidance revised to $280 to $285 million; Conference Call Today at 8:30 a.m. ET
PARSIPPANY, NJ -- (Marketwired) -- 11/08/17 --
Pacira Pharmaceuticals, Inc.
(NASDAQ: PCRX) today announced consolidated financial results for the third quarter ended September 30, 2017.
"We continue to make important progress during 2017 as we advance our strategy to expand the ro... |
|10/31/17||Pacira Pharmaceuticals Announces Timing for Third Quarter 2017 Financial Results Webcast and Conference Call|
|PARSIPPANY, N.J., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Wednesday November 8, 2017. The announcement will be followed by a conference call at 8:30 a.m. ET. Participating in the call from Pacira will be Dave Stack, chairman and chief executive officer, and other members of the company’s senior management team.
The call can be accessed by dialin... |
|10/25/17||Pacira Pharmaceuticals and TELA Bio Announce Equity Agreement|
|Pacira to invest up to $25 million in TELA Bio to enhance commercial and clinical initiatives for distinct class of novel surgical implants for soft tissue repair
PARSIPPANY, N.J. and MALVERN, Pa., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it has committed to invest up to $25 million in TELA Bio, a privately-held surgical reconstruction company that markets its proprietary OviTex™ portfolio of products for ventral hernia repair and abdom... |
|10/18/17||Pacira Pharmaceuticals Announces FDA Acceptance of sNDA for EXPAREL as a Nerve Block to Produce Regional Analgesia|
|PARSIPPANY, N.J., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its supplemental new drug application (sNDA) seeking expansion of the EXPAREL® (bupivacaine liposome injectable suspension) label to include administration via nerve block for prolonged regional analgesia. The expected action date by the FDA under the Prescription Drug User Fee Act (PDUFA) is April 6, 2018.